On Wednesday HEXO Corp HEXO reported a staggering loss of CA$152.7 million ($118 million) in the third quarter of 2022, representing a 638% year-over-year increase.
Gross profit was a loss of CA$5.27 million compared to a gain of CA$8.82 in the same quarter of 2021, while sales of CA$45.6 million were also down, 14% sequentially.
The company ended the quarter with a financial net debt of CA$166 million, according to the earnings report which came on the heels of announced amendments to the agreement with Tilray Brands TLRY, initially revealed in March.
The Canadian cannabis giant entered into a strategic partnership with HEXO - a debt financing agreement - under which it agreed to acquire $211 million of senior secured convertible notes that were originally issued by HEXO to HT Investments MA LLC. In April, Tilray signed a definitive agreement to purchase 100% of the remaining US$193 million outstanding principal balance of the senior secured convertible note.
“The agreement with HEXO delivers on both fronts as it facilitates collaboration, the sharing of best practices, and yields quantifiable operating efficiencies between two companies with unparalleled global cannabis expertise,” Irwin D. Simon, Tilray Brands’ chairman and CEO, said back then.
Earlier this week, that deal was amended to address current stock market conditions and to reduce closing risk. Separately, the company has entered into an amending agreement to the equity purchase agreement with 2692106 Ontario Inc. and KAOS Capital Ltd, which was approved by HEXO shareholders on Thursday.
Cantor Fitzgerald’s analyst Pablo Zuanic said in his recent note that the amendments suggest that Tilray would buy the outstanding convertible debt, which currently amounts to $185 million, at a 10.8% discount.
“The agreement with Tilray in essence extends the maturity of the convertible debt and halts future redemptions,” the analyst explained.
The Analyst
Zuanic retained a neutral rating on HEXO’s stock while lowering the price target to CA$0.35 from CA$0.75 on reduced sales estimates, higher share count and sectoral derating.
The Thesis
HEXO is currently valued at $100 in market cap, which according to Zuanic is a low valuation, attributing it to high debt, negative earnings and cash flow, as well as continued shareholder dilution risk.
Still, he said that Tilray could benefit from “HEXO’s travails.”
He emphasized that Tilray could leverage the current state of the markets and crisis which HECO is facing to negotiate the terms, spend less cash and eventually covert the debt in a 50% equity stake in the Canadian company, instead of 37%, according to the initial agreement.
“This all looks rather attractive for Tilray (it will pay HT Inv with US$50Mn in a convertible note due 9/1/23 and the balance either in cash or stock), as it could take 50% control of a company(HEXO) with a larger scale in the Canadian rec market (as per Hifyre) while making use of its own market cap of US$1.6Bn (vs. HEXO at US$94Mn,” Zuanic said.
Related News
- Hexo's Joint Venture Truss Beverage To Launch 15 New Cannabis-Infused Beverages
- HEXO Launches New At-the-Market Offering, Here Are The Details
- Hexo Makes Leadership Changes, Appoints New CEO & CFO
Price Action
Hexo’s shares traded 4.86% higher at $0.2180 per share during the pre-market session on Thursday morning.
Tilray’s shares traded 2.19% lower at $3.13 per share during during the pre-market session on Thursday morning.
Photo: Courtesy of Campaign Creators on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.